{ "schema_version": "chamgap-public-evidence-check-1.0", "public_id": "v3066-s3", "verdict_number": "3066", "title": "Aged garlic extract 2.4-7.2 g/day × Reduction of ex vivo platelet aggregation", "view_version": "1.0", "view_created_date": "2026-10-26", "criteria_version": "1.1", "criteria_date": "2026-10-05", "review_date": "2026-10-05", "legacy_evidence_date": "2026-09-08", "review_scope": { "materials_read": "Retained Korean/English summaries and case-specific condition/application records", "clinical_papers_directly_read": false, "new_clinical_search": false, "limitation": "Prepared from retained summaries and condition-application records. External abstracts, full texts, registration, protocols and analysis plans remain unread. Historical review records do not establish current independent clinical validation.", "date_meaning": "The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." }, "claim_context": { "population": "The broad scope mainly concerns healthy adults. The 1995 PAF candidate is retained only as a small sample of healthy men; exact eligibility, baseline status and matching to the direct AGE population remain unverified.", "comparator": "The selected question is AGE versus placebo. A direct placebo comparison matching the PAF candidate’s actual product, population, measure and time, its analysis population and between-arm contrast remain unverified.", "endpoint": "The question concerns gaps in direct PAF-induced platelet-aggregation evidence and formulation identity. The PAF endpoint name is retained, but exact measure, unit, concentration, specimen/equipment, numerical results, CI and denominators remain unverified.", "intervention": "The selected conditions concern oral AGE capsules. AGE identity, product, aging/extraction process and SAC specification of the PAF-containing garlic-preparation candidate remain unverified. Other garlic preparations are not substituted.", "dose": "The broad AGE doses of 2.4, 4.8 and 7.2 g/day belong to a 34-person dose trial. The PAF candidate’s actual route, dose, active specification and intake/adherence remain unverified; these doses are not transferred.", "duration": "The PAF candidate’s exact intake duration, blood-draw/testing time and discontinuation/washout remain unverified. The broad short-term, trial-varying description is not converted into a specific PAF duration.", "excluded_extensions": [ "Original C, 46 points, Warning and B/S/R0/I1/EX/B2/CX are historical records of the broad parent verdict. No separate PAF grade or direct effect is created.", "S01’s 34 people are the overall context of another agonist/dose trial. They are neither transferred as arm-specific PAF analysis counts or unique-replication participants nor added together.", "The 1995 PAF candidate is a garlic preparation with unverified AGE identity. Report-level no-significant-oral-effect wording does not establish a PAF-specific effect of 0, equivalence or direct refutation of identical AGE.", "The review’s 12 RCTs, 595 people and 6 positive trials are overall summary counts. Directly eligible AGE/PAF trials, results, denominators, overlap and unique replications remain unverified.", "Clinical thrombosis prevention, aspirin replacement, optimal dose and long-term persistence are separate extensions beyond this narrow gap question. Bleeding warnings are retained; unverified harms are not converted into safety or absence of events." ] }, "requirements": [ { "item_id": "N01", "question_type": "Evidence condition", "question": "Are the broad original claim and the PAF evidence-gap question distinguished?", "needed": "The original broad claim, derived boundary, target endpoint and change history.", "role": "Required", "role_reason": "The broad parent verdict is not automatically promoted to an agonist-specific effect.", "application_exception": "This question is neither a new clinical verdict nor an originally listed subclaim.", "criterion": "Preserve the original verdict claim and separately fix the question of direct AGE-versus-placebo evidence and formulation identity for PAF-induced aggregation.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "If the boundary changes, compare inclusion/exclusion for the broad original claim and derived comparison together.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The original wording is reduced ex vivo platelet aggregation. This table asks about direct AGE-versus-placebo material and formulation identity for PAF-induced aggregation. The original verdict has an empty list of separate claims; this question is not an originally listed subclaim.", "condition_status": "Met", "status_reason": "The fixed boundary distinguishes the broad original wording from the derived question without declaring a new effect.", "missingness": "Question identity and scope were checked. This does not mean a direct AGE effect on PAF was verified.", "uncertainty": "Question identity and scope were checked. This does not mean a direct AGE effect on PAF was verified.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "The original broad claim, derived boundary, target endpoint and change history." }, { "item_id": "N02", "question_type": "Evidence condition", "question": "Is the 1995 garlic preparation in the PAF material identical to the AGE product?", "needed": "The 1995 original methods: product name, manufacture/extraction, SAC, ingredients/batch, and AGE product specifications.", "role": "Required", "role_reason": "The formulation-identity gap is central to directness.", "application_exception": "Garlic preparations, raw garlic, powder, oil, allicin, black garlic and isolated SAC are not assumed to be AGE.", "criterion": "Directly verify the 1995 preparation's identity, standardization and product, and its identity with AGE capsules.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare each report's product specifications to establish formulation identity before assessing PAF eligibility.", "current_reports": [ "S01", "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "A broad AGE-capsule identity and a 1995 garlic-preparation report are retained. The latter includes PAF, but identity with AGE in product, aging/extraction process and SAC specification remains unverified.", "condition_status": "Unverified", "status_reason": "Direct product material verifying that the PAF candidate's formulation matches the selected AGE is absent.", "missingness": "AGE identity, extraction/aging process, SAC and added ingredients of the 1995 product are unverified.", "uncertainty": "AGE identity, extraction/aging process, SAC and added ingredients of the 1995 product are unverified.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "The 1995 original methods: product name, manufacture/extraction, SAC, ingredients/batch, and AGE product specifications." }, { "item_id": "N03", "question_type": "Evidence condition", "question": "Are the PAF candidate's route, actual dose and intake verified?", "needed": "The PAF candidate's administration route, product/active amount, frequency, medication records and adherence criteria.", "role": "Required", "role_reason": "Doses for other agonists are not copied as PAF trial doses.", "application_exception": "Known broad AGE doses alone do not make the PAF dose partly verified.", "criterion": "Verify the actual route, product amount, active specification and intake/adherence of the selected oral AGE and PAF candidate.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "After fixing product identity, compare actual exposure with planned doses and analyses.", "current_reports": [ "S01", "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The broad claim conditions record an oral AGE dose-ranging trial at 2.4, 4.8 and 7.2 g/day. These doses belong to the 34-person AGE report's context and cannot be transferred as doses, adherence or product amounts for the 1995 PAF candidate.", "condition_status": "Unverified", "status_reason": "The selected direct PAF candidate's route, dose/specification and intake information is unverified.", "missingness": "The PAF candidate's actual exposure, intake/adherence, dose reduction and discontinuation information is absent.", "uncertainty": "The PAF candidate's actual exposure, intake/adherence, dose reduction and discontinuation information is absent.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "The PAF candidate's administration route, product/active amount, frequency, medication records and adherence criteria." }, { "item_id": "N04", "question_type": "Evidence condition", "question": "Are the PAF candidate's actual population, baseline status and eligibility verified?", "needed": "The 1995 population/eligibility criteria, baseline table, medication/disease exclusions and actual analysis population.", "role": "Required", "role_reason": "A population label and direct eligibility are separate.", "application_exception": "This is not applied to antiplatelet co-users, thrombosis patients or all adults.", "criterion": "Verify the small-sample healthy-men clue alongside actual age, eligibility/exclusions, baseline platelet function and co-medication.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare formulation and population conditions together to assess direct applicability to the selected question.", "current_reports": [ "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The 1995 candidate is retained as a small sample of healthy men. Age, eligibility/exclusions, baseline platelet function and medication exposure remain unverified; matching the direct AGE population also first requires formulation verification.", "condition_status": "Partly verified", "status_reason": "Some population categories of the PAF candidate are known, while actual eligibility, baseline status and AGE applicability remain unresolved.", "missingness": "The healthy-men label alone does not establish the direct AGE population, medication exclusions or representativeness.", "uncertainty": "The healthy-men label alone does not establish the direct AGE population, medication exclusions or representativeness.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "The 1995 population/eligibility criteria, baseline table, medication/disease exclusions and actual analysis population." }, { "item_id": "N05", "question_type": "Evidence condition", "question": "Are the PAF candidate's intake duration and blood-draw/testing times verified?", "needed": "The PAF candidate's dosing/discontinuation schedule, blood-draw/testing times, washout and sequence.", "role": "Required", "role_reason": "Responses at different times are not combined into one effect.", "application_exception": "Durations from other AGE reports or platelet-recovery times are not newly substituted.", "criterion": "Link administration duration, discontinuation/washout, blood draw and testing times to the same PAF-response conditions.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Link temporal order and testing time to original methods/results, keeping different times separate.", "current_reports": [ "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The broad claim conditions describe only short term with durations varying across trials. The PAF candidate's exact intake duration, blood-draw/testing time and discontinuation/washout remain unverified in retained summaries.", "condition_status": "Unverified", "status_reason": "A direct schedule establishing the PAF response's timing conditions is absent.", "missingness": "A nominal short-term description cannot establish a specific PAF duration, persistence or acute response.", "uncertainty": "A nominal short-term description cannot establish a specific PAF duration, persistence or acute response.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "The PAF candidate's dosing/discontinuation schedule, blood-draw/testing times, washout and sequence." }, { "item_id": "N06", "question_type": "Evidence condition", "question": "Are the PAF endpoint clue and exact aggregation measure verified?", "needed": "PAF assay specimens, agonist concentration, equipment, maximum-aggregation/threshold definition and unit/direction.", "role": "Required", "role_reason": "The same endpoint name does not establish an identical result when measures or stimulation conditions differ.", "application_exception": "The highest-dose ADP threshold is not converted into a PAF measure.", "criterion": "Verify the PAF description, concentration, maximum aggregation/threshold/curve, unit, direction and assay conditions.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare methods and result tables, linking only matching PAF measures.", "current_reports": [ "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The 1995 evidence endpoint lists ADP, PAF and collagen aggregation. PAF concentration, assay method, maximum aggregation/threshold, unit and exact result value remain unverified.", "condition_status": "Partly verified", "status_reason": "The PAF endpoint name is known, but the actual measurement conditions remain unresolved.", "missingness": "PAF measures, agonist concentration, collection/assessment procedures and result units are absent.", "uncertainty": "PAF measures, agonist concentration, collection/assessment procedures and result units are absent.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "PAF assay specimens, agonist concentration, equipment, maximum-aggregation/threshold definition and unit/direction." }, { "item_id": "N07", "question_type": "Evidence condition", "question": "Are the 1995 opposing description and PAF-specific numerical results and intervals verified?", "needed": "The 1995 PAF-specific result tables, models/tests, effects/CI and product identity.", "role": "Required", "role_reason": "The opposing description is retained while exact result attribution is limited.", "application_exception": "No arbitrary P values, CI, effect of 0 or AGE-null verdict are created.", "criterion": "Separately verify the report-level no-significant-in-vivo-oral-effect result and PAF-specific effects, tests, intervals and AGE formulation identity.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Extract results by agonist and compare formulation matching and test direction.", "current_reports": [ "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The 1995 result is no significant in vivo oral effect, and PAF appears among the endpoints. PAF-specific estimates, CI, tests, denominators and AGE identity remain unverified. Non-significance is not converted into an effect of 0 or equivalence.", "condition_status": "Partly verified", "status_reason": "The opposing report context is retained, while direct PAF-specific effects and precision remain unresolved.", "missingness": "The report-level non-significance wording alone cannot establish a PAF-specific effect of 0 or AGE inefficacy.", "uncertainty": "The report-level non-significance wording alone cannot establish a PAF-specific effect of 0 or AGE inefficacy.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "The 1995 PAF-specific result tables, models/tests, effects/CI and product identity." }, { "item_id": "N08", "question_type": "Evidence condition", "question": "Is a direct AGE-versus-placebo comparison result for PAF verified?", "needed": "Placebo-comparison methods, results and arm-specific analysis tables for PAF with verified AGE formulation.", "role": "Required", "role_reason": "A gap in direct results must also be retained in the table.", "application_exception": "Unverified information within the retained scope is not a conclusion that 0 studies exist worldwide.", "criterion": "Verify the actual placebo comparison and result for matching AGE product, population, PAF measure and time.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Fix product identity and the PAF measure before assessing direct comparison material against eligibility criteria.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "A direct AGE-versus-placebo PAF result is unverified within the current 3 evidence entries/3 citations. The 1995 candidate has unverified product identity, and the 34-person AGE report concerns other agonists.", "condition_status": "Unverified", "status_reason": "Material or gateway existence differs from an eligible direct PAF result, which is currently unverified.", "missingness": "The direct AGE placebo comparison, measure, population, time, denominator and effect for PAF remain unverified.", "uncertainty": "The direct AGE placebo comparison, measure, population, time, denominator and effect for PAF remain unverified.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Placebo-comparison methods, results and arm-specific analysis tables for PAF with verified AGE formulation." }, { "item_id": "N09", "question_type": "Evidence condition", "question": "Are the PAF candidate's blinding, allocation and co-intervention procedures verified?", "needed": "The 1995 original methods, allocation/concealment, baseline tables, co-interventions/rescue treatment and blinding material.", "role": "Required", "role_reason": "A design label does not resolve allocation or measurement problems.", "application_exception": "The double-blind label does not add randomization, a parallel design or absence of bias.", "criterion": "Verify the candidate's double-blind placebo design alongside actual allocation, concealment, co-interventions, rescue treatment and assessment blinding.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare methods, baseline and co-intervention records for arm-specific differences that could explain PAF results.", "current_reports": [ "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The 1995 candidate is retained as a double-blind placebo trial. Details of randomization status, allocation/concealment, baseline balance, co-interventions/rescue treatment and measurement blinding are unverified.", "condition_status": "Partly verified", "status_reason": "Blinding and placebo labels are known, but actual design/conduct and intervention-attribution material remain unresolved.", "missingness": "The candidate's allocation, concealment, co-intervention/rescue treatment and assessment procedures remain unverified.", "uncertainty": "The candidate's allocation, concealment, co-intervention/rescue treatment and assessment procedures remain unverified.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "The 1995 original methods, allocation/concealment, baseline tables, co-interventions/rescue treatment and blinding material." }, { "item_id": "N10", "question_type": "Evidence condition", "question": "Were the 34-person AGE results kept separate from direct PAF results?", "needed": "S01's full agonist plans, result tables, specimen/population links and whether PAF was included.", "role": "Required", "role_reason": "Other favorable signals are not read as effects on the selected PAF response.", "application_exception": "Absence from the current summary does not establish non-reporting or non-measurement throughout the paper.", "criterion": "Retain partial collagen/epinephrine reductions and the weak highest-dose ADP threshold in their original report without transferring them to PAF.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare planned agonists and result tables to distinguish PAF measurement, omission and non-planning.", "current_reports": [ "S01" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "S01 is a 34-person AGE dose-ranging trial. Results include partial collagen/epinephrine reductions and a weak highest-dose ADP threshold signal; a current PAF result is not specified.", "condition_status": "Met", "status_reason": "Known S01 results were retained with their agonists rather than promoted to PAF results.", "missingness": "The original boundary of other endpoint results was checked. Whether S01 actually measured PAF and the reason for any omission remain unverified because the original paper is unread.", "uncertainty": "The original boundary of other endpoint results was checked. Whether S01 actually measured PAF and the reason for any omission remain unverified because the original paper is unread.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "S01's full agonist plans, result tables, specimen/population links and whether PAF was included." }, { "item_id": "N11", "question_type": "Evidence condition", "question": "Are PAF allocation, measurement and analysis n and missingness verified?", "needed": "PAF-specific arm flowcharts, analysis populations, completion/missingness n and handling rules.", "role": "Required", "role_reason": "Another report's total is not transferred as the selected-response denominator.", "application_exception": "Exact n is not inferred from the small-sample label, and 34 and 595 are not added.", "criterion": "Verify the PAF candidate's arm-specific allocation/completion/measurement/analysis n, missingness handling and direct AGE analysis population.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Link paper flow and assay-specific population tables to assess cross-use of denominators and selective losses.", "current_reports": [ "S01", "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The 1995 report retains only a small sample of healthy men. Arm-specific PAF n, losses, missingness and analysis population are unverified. The 34 people in another AGE report are not the PAF analysis n.", "condition_status": "Unverified", "status_reason": "Without exact selected-response denominators and missingness handling, the direct estimate's population cannot be verified.", "missingness": "PAF allocation, measurement, analysis and completion denominators, loss reasons and handling material are absent.", "uncertainty": "PAF allocation, measurement, analysis and completion denominators, loss reasons and handling material are absent.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "PAF-specific arm flowcharts, analysis populations, completion/missingness n and handling rules." }, { "item_id": "N12", "question_type": "Evidence condition", "question": "Are between/within-arm contrasts, models, variance and CI for the PAF estimate verified?", "needed": "PAF-specific analysis plans, estimates, variance/CI and the basis for an important difference.", "role": "Required", "role_reason": "Broad original axes do not provide individual PAF analyses or intervals.", "application_exception": "Non-significance is not interpreted as equivalence, and no new effects, CI or percentage of conditions met are calculated.", "criterion": "Verify the actual effect of interest, analysis method, adjustment, variance/CI and clinical-importance criteria for PAF.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare the actual estimand and intervals with verified important-difference criteria without new calculations.", "current_reports": [ "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "PAF-specific between/within-arm contrasts, effect values, SD/SE, CI, adjustment and important-difference criteria remain unverified. Report-level non-significance or broad EX/CX axes do not substitute for them.", "condition_status": "Unverified", "status_reason": "Direct data for PAF estimates and variance are absent.", "missingness": "Without PAF effect definitions, models, variance, intervals and important-difference material, sufficiency is not assessed.", "uncertainty": "Without PAF effect definitions, models, variance, intervals and important-difference material, sufficiency is not assessed.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "PAF-specific analysis plans, estimates, variance/CI and the basis for an important difference." }, { "item_id": "N13", "question_type": "Evidence condition", "question": "Do prespecified PAF endpoints, times and analyses agree with published results?", "needed": "Original registration/protocols, PAF plans, multiplicity rules, result tables and change history.", "role": "Required", "role_reason": "Material is needed to assess possible favorable selection among multiple agonists and doses.", "application_exception": "Unobtained registration is not converted into confirmed non-registration or selective reporting.", "criterion": "Verify planned PAF concentrations/measures, doses, times, analyses and multiplicity handling against published reports.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare initial plans and agonist-specific published results, distinguishing planning, omission and changes.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "All 3 original evidence registration fields say not verified. Agreement or changes between prespecified PAF endpoints, analysis/multiplicity plans and actual results remain unverified.", "condition_status": "Unverified", "status_reason": "Direct registration/planning material is absent, so PAF prespecification and selective reporting cannot be established.", "missingness": "A comparison of PAF plans, registration, analysis plans and publications is absent.", "uncertainty": "A comparison of PAF plans, registration, analysis plans and publications is absent.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Original registration/protocols, PAF plans, multiplicity rules, result tables and change history." }, { "item_id": "N14", "question_type": "Evidence condition", "question": "Are overall review results and the directly eligible PAF/AGE subset verified?", "needed": "Review included-trial tables, results by product/agonist/time/analysis and overlap tables.", "role": "Required", "role_reason": "Review averages or positive-report counts are not counted as direct replication.", "application_exception": "The 6 positive reports are not read as 6 positive PAF trials, and heterogeneity is not recalculated as PAF conflict.", "criterion": "Distinguish the broad review record of 12 RCTs, 595 people and 6 positive/rest-null trials from AGE/PAF-specific products, measures and trial results.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Separate included trials by formulation and agonist, comparing both positive and no-difference results.", "current_reports": [ "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The 2022 review reports 12 RCTs, 595 people, 6 positive and the rest null, with heterogeneity preventing a conclusion. PAF-specific eligible AGE trials, results and denominators are unverified in the current summary.", "condition_status": "Partly verified", "status_reason": "The review's overall direction and limitations are known, while its eligible selected PAF subset remains unresolved.", "missingness": "Overall review and positive-result counts are not PAF AGE trial counts, participant counts or effects.", "uncertainty": "Overall review and positive-result counts are not PAF AGE trial counts, participant counts or effects.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Review included-trial tables, results by product/agonist/time/analysis and overlap tables." }, { "item_id": "N15", "question_type": "Evidence condition", "question": "Is overlap between the same AGE trial and review-included trials verified?", "needed": "Review included-trial tables, registration/paper identifiers, recruitment sites/periods and product/endpoint links.", "role": "Required", "role_reason": "The same 34 people or the review's 595 people are not recounted as independent participants.", "application_exception": "No 34+595 total or dose/agonist-specific independent-trial counts are automatically created.", "criterion": "Retain S01's multiple doses/agonists as the same 34-person context and verify S02 identity and overlap between S03 included trials and reports.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Build report-trial-population-endpoint links to connect multiple reports and review recitations to the same families.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "S01 contains multiple agonist results from a 34-person dose trial. S02 is another preparation's 1995 report; S03 is a review of 12 RCTs. Review inclusion, overlap with S01/S02 and unique direct PAF study families remain unverified.", "condition_status": "Partly verified", "status_reason": "Multiple results from one trial and the review type are known, while complete study-family/overlap links remain unresolved.", "missingness": "Included-trial identities, cohorts, preparations, PAF measures and unique selected-response replication counts remain unverified.", "uncertainty": "Included-trial identities, cohorts, preparations, PAF measures and unique selected-response replication counts remain unverified.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Review included-trial tables, registration/paper identifiers, recruitment sites/periods and product/endpoint links." }, { "item_id": "N16", "question_type": "Evidence condition", "question": "Is independent replication under matching AGE/PAF conditions verified?", "needed": "Unique-trial results with verified formulation/PAF conditions and study-family links.", "role": "Required", "role_reason": "Broad original independence labels are not inherited by the individual selected response.", "application_exception": "Current unverified status does not establish 0 studies or an AGE effect of 0.", "criterion": "Verify unique direct replication results for matching formulation, population, PAF measure, comparison and time.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Fix direct eligibility before comparing results and condition differences across unique study families.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The direct AGE/PAF conditions themselves and unique independent replications are unverified in current summaries. The original independent-opposing-result label is historical wording for the broad 1995 report.", "condition_status": "Unverified", "status_reason": "Other-preparation candidates or the overall review cannot establish direct replication of the selected response.", "missingness": "Unique direct AGE PAF trials and the distribution of replication results remain unverified.", "uncertainty": "Unique direct AGE PAF trials and the distribution of replication results remain unverified.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Unique-trial results with verified formulation/PAF conditions and study-family links." }, { "item_id": "N17", "question_type": "Evidence condition", "question": "Are each report's funding clues and product/author independence verified?", "needed": "Original reports' funding/COI, product provision, authors/institutions/patents and included-trial tables.", "role": "Supplementary; required for independence claims", "role_reason": "Unverified funding is not converted into independent support or absence of bias.", "application_exception": "Product support alone does not automatically exclude results, and generic English funding wording is not treated as actual verification.", "criterion": "Retain unverified S01 product-support details, unverified S02 funding and S03 academic/mixed funding, and verify the PAF candidate's product/author/COI relationships.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare funding and product/author relationships report by report, retaining unverified independence.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "S01 product-support details and S02 funding are unverified. S03 is academic research with mixed original-trial funding. Product provision, author employment/patents, COI and AGE product relationships for the PAF candidate remain unverified.", "condition_status": "Partly verified", "status_reason": "Some report-specific funding records exist, while selected-response independence details remain unresolved.", "missingness": "Detailed product, author/institution, patent, COI and review-included-trial funding links are absent.", "uncertainty": "Detailed product, author/institution, patent, COI and review-included-trial funding links are absent.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Original reports' funding/COI, product provision, authors/institutions/patents and included-trial tables." }, { "item_id": "N18", "question_type": "Evidence condition", "question": "Are bleeding events, collection, denominators and timing under the same exposure verified?", "needed": "Exposure with matching formulation: AE definitions, collection/severity, event/person counts, exposure/follow-up, discontinuation and comparisons.", "role": "Supplementary; required for harm claims", "role_reason": "Statements that clinical events were not measured differ from personal bleeding safety.", "application_exception": "Unverified bleeding is not written as 0 events or safety, and 34/595 are not reused as harm denominators.", "criterion": "Distinguish aggregation assays from actual bleeding, severe and discontinuation event definitions, collection, exposed/event participants, comparisons and follow-up.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Separate aggregation results from safety populations/follow-up and compare events, timing and denominators.", "current_reports": [ "S01", "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The original text says clinical thrombosis or bleeding was not measured in these trials. Bleeding events, person counts, collection, discontinuation and comparison/follow-up denominators for the PAF candidate remain unverified.", "condition_status": "Unverified", "status_reason": "Platelet-response material does not provide actual bleeding-event counts.", "missingness": "Harm collection, event/person counts, denominators, duration and discontinuation for matching PAF/AGE exposure are absent.", "uncertainty": "Harm collection, event/person counts, denominators, duration and discontinuation for matching PAF/AGE exposure are absent.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Exposure with matching formulation: AE definitions, collection/severity, event/person counts, exposure/follow-up, discontinuation and comparisons." }, { "item_id": "N19", "question_type": "Evidence condition", "question": "Are the original bleeding warning and direct co-medication/vulnerable-group data verified?", "needed": "Group-specific formulation, exposure, events, follow-up/alternative explanations and warning sources.", "role": "Supplementary; required for the stated safety claim", "role_reason": "Experimental trial-population results are not extended to special-population safety.", "application_exception": "Retaining a warning is neither new harm-causality/incidence adjudication nor a dosing prescription.", "criterion": "Distinguish original warnings for anticoagulants/antiplatelets, bleeding disorders and perioperative use from direct exposure/events, alternative causes and interaction material.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare original warning evidence and group-specific safety material separately without certifying personal safety.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The original warning prohibits unsupervised use with anticoagulants/antiplatelets, bleeding disorders and around surgery. Direct AGE/PAF exposure, events, follow-up and interaction magnitude in these groups remain unverified.", "condition_status": "Partly verified", "status_reason": "The original warning names the groups, but direct group-specific information remains unresolved.", "missingness": "Group-specific harms, alternative causes/adjustment and long-term/rare-event material remain unverified.", "uncertainty": "Group-specific harms, alternative causes/adjustment and long-term/rare-event material remain unverified.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Group-specific formulation, exposure, events, follow-up/alternative explanations and warning sources." }, { "item_id": "N20", "question_type": "Evidence condition", "question": "Does the PAF response answer thrombosis prevention or aspirin replacement?", "needed": "A separate event question's definition, comparator, follow-up, denominator and clinical results.", "role": "Supplementary; required only for clinical extensions", "role_reason": "Experimental aggregation assays and clinical prevention are different questions.", "application_exception": "Not applicable does not mean no events, a PAF effect of 0 or safety certification.", "criterion": "Separate the selected ex vivo response gap from clinical thrombosis/bleeding and treatment-replacement questions.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "If an event question is requested, review separate clinical endpoints and long-term/event-follow-up studies.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "Direct material for the PAF response itself is unverified. No thrombosis-prevention, thrombolysis, aspirin-replacement or bleeding-safety claim is made.", "condition_status": "Not applicable", "status_reason": "Clinical events/replacement are not direct results of this aggregation-gap question, so separate clinical confirmation is not imposed as a current required condition.", "missingness": "Direct clinical-event effects were not checked in this table. Ex vivo gaps are not added to event-effect gaps.", "uncertainty": "Direct clinical-event effects were not checked in this table. Ex vivo gaps are not added to event-effect gaps.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "A separate event question's definition, comparator, follow-up, denominator and clinical results." }, { "item_id": "N21", "question_type": "Evidence condition", "question": "Are optimal dose, long-term persistence and special subgroups part of this question?", "needed": "If extension is requested: direct PAF dose comparisons, follow-up and prespecified subgroup/interaction material.", "role": "Supplementary; required only for extension claims", "role_reason": "A narrow gap question does not impose every extension study.", "application_exception": "The highest-dose signal for another agonist does not establish the optimal PAF dose.", "criterion": "Distinguish direct PAF identity/result gaps from dose optimization, discontinuation/long-term and subgroup questions.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "After direct PAF conditions are verified, assess eligible designs/results for each separate extension question.", "current_reports": [ "S01", "S02" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "This question checks direct AGE PAF evidence and formulation identity. Optimal dose, persistence after discontinuation and special-subgroup effects are not newly claimed.", "condition_status": "Not applicable", "status_reason": "These extension obligations lie outside the current question; the broad dose trial is not converted into PAF dose optimization.", "missingness": "Original identity/result gaps remain, but separate extensions are not automatically made required.", "uncertainty": "Original identity/result gaps remain, but separate extensions are not automatically made required.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "If extension is requested: direct PAF dose comparisons, follow-up and prespecified subgroup/interaction material." }, { "item_id": "N22", "question_type": "Evidence condition", "question": "Were local-summary reading and unread linked external materials distinguished?", "needed": "Subsequent material-specific access/acquisition/reading records, versions, original locations and physical material.", "role": "Required", "role_reason": "Bibliographic existence is not promoted to full-text reading or acquisition of eligible results.", "application_exception": "Unattempted external access is not called access failure, and report-level historical full-text access is not inherited by a constructed DOI gateway.", "criterion": "Distinguish reading all 3 evidence entries, 3 citations and Korean/English text from unattempted, unacquired and unread external PubMed/DOI/full-text material by material.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "In authorized subsequent review, record external acquisition/reading as separate events and compare with retained summaries.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The complete retained summary, 3 evidence entries and 3 citations were read. External PubMed/DOI gateways and original papers remain unattempted, unacquired and unread; no direct PAF result was newly acquired.", "condition_status": "Met", "status_reason": "Actual local reading was separated from unread external material and linked to exact summary locations and identity checks.", "missingness": "The current summary-reading scope was checked. External responses, actual document forms, abstracts/full texts and licenses remain unverified.", "uncertainty": "The current summary-reading scope was checked. External responses, actual document forms, abstracts/full texts and licenses remain unverified.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Subsequent material-specific access/acquisition/reading records, versions, original locations and physical material." }, { "item_id": "N23", "question_type": "Evidence condition", "question": "Were the original review date, correction date and individual access dates distinguished?", "needed": "Historical material-specific access/version records and complete before/after correction versions.", "role": "Required", "role_reason": "A global review date is not an individual external access date.", "application_exception": "Historical agonist-separation wording is not converted into current original-paper reading.", "criterion": "Distinguish the original review-date field 2026-09-08, correction date 2026-09-14 and current review time; retain absent material-specific access-date/level fields as unrecorded.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Link and compare original review, correction and actual access events separately.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "The original review date 2026-09-08 and generic-English-wording correction date 2026-09-14 are retained. Material-specific access-date, level and location fields are absent and unrecorded; current local reading has its own actual timestamp.", "condition_status": "Met", "status_reason": "Event-specific dates and absent fields were retained without backdating historical/current reading.", "missingness": "Historical material-specific access dates and full-text scope remain unverified. Only separation of the dates was checked.", "uncertainty": "Historical material-specific access dates and full-text scope remain unverified. Only separation of the dates was checked.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Historical material-specific access/version records and complete before/after correction versions." }, { "item_id": "N24", "question_type": "Evidence condition", "question": "Are search/selection records available to verify the complete current PAF/AGE evidence?", "needed": "Historical queries/dates, selection/exclusion, unpublished/correction/retraction checks and product/agonist-specific candidate logs.", "role": "Required", "role_reason": "An absence statement requires an actual reviewed scope.", "application_exception": "0 new searches are not reported as 0 PAF studies or a complete current review.", "criterion": "Verify queries, dates, selection/exclusion, unpublished/correction-check logs and the scope of complete current evidence for the PAF/AGE question. Separately display current retained-summary reading and the absence of new searching.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "In an authorized separate update, fix the product/PAF question, reproduce the search scope and compare potentially omitted candidates.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "Unverified direct PAF results are limited to the current 3 evidence entries/3 citations in retained summaries. The original research-description separation of the 34-person trial, review and opposing trial is historical wording; no new exhaustive search, registration/unpublished or retraction check was performed.", "condition_status": "Unverified", "status_reason": "Search logs and material establishing completeness beyond the current scope are absent.", "missingness": "Checking PAF/AGE literature, unpublished reports and corrections/retractions beyond current material was not performed. Study absence is not established.", "uncertainty": "Checking PAF/AGE literature, unpublished reports and corrections/retractions beyond current material was not performed. Study absence is not established.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "Historical queries/dates, selection/exclusion, unpublished/correction/retraction checks and product/agonist-specific candidate logs." }, { "item_id": "N25", "question_type": "Evidence condition", "question": "Were the original broad C46, axes and all results distinguished from a derived grade?", "needed": "The complete original summary, input identity, boundary/verdict/correction events and separate-grade policy.", "role": "Required", "role_reason": "The historical broad parent verdict does not become an individual efficacy status for the selected response.", "application_exception": "Unverified actual observations are not filled with the number 0 or no effect.", "criterion": "Retain original 3066 C46/axes/Warning, values, empty separate-claim list, generic English wording and corrections; state that the separate PAF grade is unrecorded.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, funding and harms in the retained reports. Detailed conditions are Chamgap’s own application.", "condition_origin": "These are in-house application conditions for direct PAF evidence and AGE formulation identity, developed with knowledge of the retained content. They do not establish blinding, clinical preregistration, official-method certification or independent clinical validation.", "proposed_research": "Compare complete original text, preserved case values and change events to check that no new derived verdict was created.", "current_reports": [ "S01", "S02", "S03" ], "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "observation": "Original C46, B/S/R0/I1/EX/B2/CX, Warning and all original results are retained as historical records of the broad parent verdict. The individual PAF grade is unrecorded. Generic English sample-size/result wording does not create selected-response values or successful access.", "condition_status": "Met", "status_reason": "Complete original typed values and derived identity were retained without creating a separate effect or grade.", "missingness": "Preservation of the broad parent verdict was checked. This table does not newly establish PAF efficacy, clinical sufficiency or method certification.", "uncertainty": "Preservation of the broad parent verdict was checked. This table does not newly establish PAF efficacy, clinical sufficiency or method certification.", "review_date": "2026-10-05", "reading_status": "Full text not read · Stored summary read", "additional_material": "The complete original summary, input identity, boundary/verdict/correction events and separate-grade policy." } ], "reports": [ { "report_id": "S01", "title": "The effects of aged garlic extract on platelet aggregation and adhesion in humans", "url": "https://pubmed.ncbi.nlm.nih.gov/11238801/", "report_type": "A retained bibliographic/evidence summary. The actual external material type/version and full-text provision remain unverified.", "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "study_family": "S01 concerns other agonists/doses in a shared AGE trial. Direct PAF results and denominators remain unverified.", "independent_replication": "Other-agonist results from the same trial are not counted as direct PAF replication.", "observed_result": "34 people; partial collagen/epinephrine reductions; a weak ADP threshold signal only at the highest dose. A direct result for the selected response is unverified in the current summary.", "result_level": "Context from the retained summary; direct AGE/PAF observations, analysis denominators and numerical results remain unverified.", "source_evidence_date": "2026-09-08", "materials": [ { "material_type": "External PubMed bibliographic/abstract gateway", "public_status": "External access not attempted; not acquired; unread", "access_status": "External access not attempted; not acquired", "acquired": false, "actually_read": "Not read", "as_of": "2026-10-05", "qualification": "This is the retained PubMed link. Its current response, abstract provision/content and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." }, { "material_type": "External DOI/publisher gateway", "public_status": "External access not attempted; not acquired; unread", "access_status": "External access not attempted; not acquired", "acquired": false, "actually_read": "Not read", "as_of": "2026-10-05", "qualification": "This is the retained DOI link. Its current response, publisher provision, original-text version and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." }, { "material_type": "Original paper full text; direct location/version unverified", "public_status": "External access not attempted; not acquired; unread", "access_status": "External access not attempted; not acquired", "acquired": false, "actually_read": "Not read", "as_of": "2026-10-05", "qualification": "The original paper’s direct physical location, version, provision, public availability, acquisition and actual reading remain unverified. No direct URL is invented. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." }, { "material_type": "Retained verdict summary", "public_status": "Retained verdict summary read", "access_status": "Retained copy acquired; summary read", "acquired": true, "actually_read": "Stored existing review summary read", "as_of": "2026-10-05", "qualification": "Relevant retained summary, evidence and citation content was read. This is not the original clinical paper’s bytes or full text. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." } ], "links": [ { "label": "PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/11238801/" } ] }, { "report_id": "S02", "title": "Effect of a garlic preparation on in vitro platelet aggregation in healthy subjects", "url": "https://pubmed.ncbi.nlm.nih.gov/8582091/", "report_type": "A retained bibliographic/evidence summary. The actual external material type/version and full-text provision remain unverified.", "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "study_family": "S02 reports another PAF-containing garlic preparation. AGE product identity and direct eligibility remain unverified.", "independent_replication": "A report with unverified formulation, measure and comparison does not establish independent replication or refutation of identical AGE/PAF.", "observed_result": "A small sample of healthy men; ADP, PAF and collagen; no significant in vivo oral effect. AGE product identity and selected-response-specific estimates/CI remain unverified.", "result_level": "Context from the retained summary; direct AGE/PAF observations, analysis denominators and numerical results remain unverified.", "source_evidence_date": "2026-09-08", "materials": [ { "material_type": "External PubMed bibliographic/abstract gateway", "public_status": "External access not attempted; not acquired; unread", "access_status": "External access not attempted; not acquired", "acquired": false, "actually_read": "Not read", "as_of": "2026-10-05", "qualification": "This is the retained PubMed link. Its current response, abstract provision/content and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." }, { "material_type": "External DOI/publisher gateway", "public_status": "External access not attempted; not acquired; unread", "access_status": "External access not attempted; not acquired", "acquired": false, "actually_read": "Not read", "as_of": "2026-10-05", "qualification": "This is the retained DOI link. Its current response, publisher provision, original-text version and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." }, { "material_type": "Original paper full text; direct location/version unverified", "public_status": "External access not attempted; not acquired; unread", "access_status": "External access not attempted; not acquired", "acquired": false, "actually_read": "Not read", "as_of": "2026-10-05", "qualification": "The original paper’s direct physical location, version, provision, public availability, acquisition and actual reading remain unverified. No direct URL is invented. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." }, { "material_type": "Retained verdict summary", "public_status": "Retained verdict summary read", "access_status": "Retained copy acquired; summary read", "acquired": true, "actually_read": "Stored existing review summary read", "as_of": "2026-10-05", "qualification": "Relevant retained summary, evidence and citation content was read. This is not the original clinical paper’s bytes or full text. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." } ], "links": [ { "label": "PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/8582091/" } ] }, { "report_id": "S03", "title": "Garlic supplementation and platelet aggregation: a systematic review of randomized controlled trials", "url": "https://pubmed.ncbi.nlm.nih.gov/36222178/", "report_type": "A retained bibliographic/evidence summary. The actual external material type/version and full-text provision remain unverified.", "existence": "Stored research and bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product, funding and harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific condition/application records were read. External abstracts, full texts, registration, protocols and analysis plans remain unread, with access not attempted.", "study_family": "S03 is an overall review; its included trials matching selected AGE/PAF and overlap with original reports remain unverified.", "independent_replication": "Overall review counts are not direct PAF replication counts. Actual included trials, products and overlap remain unverified.", "observed_result": "12 RCTs and 595 people; 6 positive and the rest null; heterogeneity prevents a conclusion. Included trials, results and overlap for the selected response remain unverified.", "result_level": "Context from the retained summary; direct AGE/PAF observations, analysis denominators and numerical results remain unverified.", "source_evidence_date": "2026-09-08", "materials": [ { "material_type": "External PubMed bibliographic/abstract gateway", "public_status": "External access not attempted; not acquired; unread", "access_status": "External access not attempted; not acquired", "acquired": false, "actually_read": "Not read", "as_of": "2026-10-05", "qualification": "This is the retained PubMed link. Its current response, abstract provision/content and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." }, { "material_type": "External DOI/publisher gateway", "public_status": "External access not attempted; not acquired; unread", "access_status": "External access not attempted; not acquired", "acquired": false, "actually_read": "Not read", "as_of": "2026-10-05", "qualification": "This is the retained DOI link. Its current response, publisher provision, original-text version and public access were not checked. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." }, { "material_type": "Original paper full text; direct location/version unverified", "public_status": "External access not attempted; not acquired; unread", "access_status": "External access not attempted; not acquired", "acquired": false, "actually_read": "Not read", "as_of": "2026-10-05", "qualification": "The original paper’s direct physical location, version, provision, public availability, acquisition and actual reading remain unverified. No direct URL is invented. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." }, { "material_type": "Retained verdict summary", "public_status": "Retained verdict summary read", "access_status": "Retained copy acquired; summary read", "acquired": true, "actually_read": "Stored existing review summary read", "as_of": "2026-10-05", "qualification": "Relevant retained summary, evidence and citation content was read. This is not the original clinical paper’s bytes or full text. A report linked to retained summaries and citations. External gateways, full texts, registration, protocols and analysis plans remain unread, with access not attempted in this conversion. The displayed material date is the case-record review date. Original verdict review, correction and case review dates are not historical access dates for individual external materials or search cut-offs. Historical external access dates and reading scope are unrecorded; external access was not attempted in this conversion." } ], "links": [ { "label": "PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/36222178/" } ] } ], "method_sources": [ { "id": "M03", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03", "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13", "official_principle": "Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M04", "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04", "section": "§4.5, §4.6.1–4.6.3, MECIR C42", "official_principle": "Distinguish studies from reports and link them; do not omit a study solely because results are unreported.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M08", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08", "section": "§8.1–8.2.3, Table 8.2.a", "official_principle": "Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M15", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15", "section": "§15.2.4, §15.3.1–15.3.3", "official_principle": "Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M19", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19", "section": "§19.1.2, §19.2.1–19.2.4", "official_principle": "Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." } ], "status_dictionary": { "Met": "Limited verification of the retained identity, observation or scope required by this row. This is separate from clinical sufficiency or full-text certification.", "Partly verified": "Some facts needed by the question are known, while the stated analysis, population, formulation or denominator remains unverified.", "Unverified": "Direct information for this question is unverified in the retained scope. This does not mean an effect of 0, no studies, no harm or an unreviewed table.", "Not applicable": "A specific extension obligation lies outside the narrow question. This does not substitute for unread or unverified material.", "Not applicable (alias)": "A grey-display alias of Not applicable.", "Not read": "The external material was not directly read in the current work. This is separate from reading the retained local summary.", "Conflicting data": "Actual disagreement between reports under the same conditions. Differences between other questions alone do not establish conflict." }, "study_overlap": { "state": "Unverified", "unique_trial_count": null, "unique_participant_count": null, "reason": "S01 concerns other agonists in a shared 34-person AGE dose trial. S02 reports another PAF-containing preparation with unverified AGE identity; S03 is a review of 12 RCTs and 595 people. Unique direct PAF trials/participants and review overlap remain unverified." }, "history": [ { "date": "2026-10-26", "kind": "Separation of public-facing pages and materials", "view_version": "1.0", "change": "The public view and materials were prepared from the existing 25 items. No new clinical search, verification-state change or scoring was performed." } ], "language": "en", "translation_date": "2026-10-26" }